Is IL-10 a good target to inhibit choroidal neovascularisation in age-related macular disease?
Lightman
Sue
S
Institute of Ophthalmology, London, United Kingdom. s.lightman@ucl.ac.uk
Calder
Virginia
V
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D004195:Disease Models, Animal; D006801:Humans; D016753:Interleukin-10 / Q000235:genetics / Q000276:immunology* / Q000502:physiology; D008264:Macrophages / Q000187:drug effects / Q000502:physiology; D008268:Macular Degeneration / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D051379:Mice; D018345:Mice, Knockout; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D016753:Interleukin-10